Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models

Kiran Shekar1,2*, Jason A. Roberts3, Adrian G. Barnett4, Sara Diab1, Steven C. Wallis3, Yoke L. Fung5 and John F. Fraser1

Abstract

Introduction: Ex vivo experiments in extracorporeal membrane oxygenation (ECMO) circuits have identified octanol-water partition coefficient (logP, a marker of lipophilicity) and protein binding (PB) as key drug factors affecting pharmacokinetics (PK) during ECMO. Using ovine models, in this study we investigated whether these drug properties can be used to predict PK alterations of antimicrobial drugs during ECMO.

Methods: Single-dose PK sampling was performed in healthy sheep (HS, n = 7), healthy sheep on ECMO (E24H, n = 7) and sheep with smoke inhalation acute lung injury on ECMO (SE24H, n = 6). The sheep received eight study antimicrobials (ceftriaxone, gentamicin, meropenem, vancomycin, doripenem, ciprofloxacin, fluconazole, caspofungin) that exhibit varying degrees of logP and PB. Plasma drug concentrations were determined using validated chromatographic techniques. PK data obtained from a non-compartmental analysis were used in a linear regression model to predict PK parameters based on logP and PB.

Results: We found statistically significant differences in pH, haemodynamics, fluid balance and plasma proteins between the E24H and SE24H groups (p < 0.001). logP had a strong positive linear relationship with steady-state volume of distribution (Vss) in both the E24H and SE24H groups (p < 0.001) but not in the HS group (p = 0.9) and no relationship with clearance (CL) in all study groups. Although we observed an increase in CL for highly PB drugs in ECMO sheep, PB exhibited a weaker negative linear relationship with both CL (HS, p = 0.01; E24H, p < 0.001; SE24H, p < 0.001) and Vss (HS, p = 0.01; E24H, p = 0.004; SE24H, p = 0.05) in the final model.

Conclusions: Lipophilic antimicrobials are likely to have an increased Vss and decreased CL during ECMO. Protein-bound antimicrobial agents are likely to have reductions both in CL and Vss during ECMO. The strong relationship between lipophilicity and Vss seen in both the E24H and SE24H groups indicates circuit sequestration of lipophilic drugs. These findings highlight the importance of drug factors in predicting antimicrobial drug PK during ECMO and should be a consideration when performing and interpreting population PK studies.

* Correspondence: kiran.shekar@health.qld.gov.au
1 Critical Care Research Group, The Prince Charles Hospital, Rode Road, Chermside, QLD 4032, Australia
2 Discipline of Anaesthesia and Critical Care, The University of Queensland, Brisbane QLD, Australia
Full list of author information is available at the end of the article

© 2015 Shekar et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction

With refinements in technology, extracorporeal membrane oxygenation (ECMO) and extracorporeal life support (ECLS) in general now represent a significant development in intensive care practice [1–4]. A wide range of acutely ill patients with cardiorespiratory failure are now being successfully rescued with ECLS therapies, but clinicians await definitive evidence supporting their use. Invasive ECLS therapies such as ECMO are complex supportive interventions, and outcomes rely not only on technology but also on user experience [5]; optimisation of other aspects of intensive care unit (ICU) management, established processes and other available services in each centre; and optimisation of pharmacotherapy to minimise and/or treat complications [6].

A variety of infectious and non-infectious conditions may result in severe cardiorespiratory failure, and an infection or sepsis is no longer considered a contraindication for ECMO [7]. Similarly, patients on ECMO may develop a variety of ICU-acquired infections that may necessitate antimicrobial therapy. Optimal antimicrobial therapy in these patients is a balance between potency, bacterial susceptibility and exposure [8, 9]. The authors of a recent review identified 30.1 infections per 1000 days of ECMO among patients with infections who were experiencing prolonged ICU and hospital lengths of stay [10]. The authors of another review [11] identified a total of 2418 infections in 20,741 (12 %) ECMO cases, with increased morbidity seen in patients with infections. Antimicrobial therapy is commonly prescribed in ECMO patients, and optimisation of dosing is central not only to improving patient outcomes but also to minimising the emergence of microbial resistance [8].

However, ECMO is known to induce significant pharmacokinetic (PK) alterations [12] in critically ill patients who already exhibit significantly altered PK [13], raising concerns of therapeutic failure or toxicity. Neonatal studies have shown major variations in antibiotic PK during ECMO [12, 14–16], and there is an emerging body of literature to support this in adult patients [17–20]. The interaction between the drug, the ECMO device and the disease are complex; hence clinical population PK studies alone may not be able to advance understanding of mechanisms behind altered PK in ECMO patients. This calls for systematic investigation [21] of each of these factors. To this end, experimental studies [22, 23] using circuit components used in adults have shown significant drug sequestration in ECMO circuits based on physicochemical properties of the drug, such as drug stability, octanol-water coefficient (logP, a marker of lipophilicity) and protein binding (PB).

Ex vivo experimental conditions are quite different from in vivo scenarios. The addition of an extracorporeal circuit to a critically ill patient may result in profound PK alterations, and appreciating the relative contributions of drug, device and disease factors to altered PK is challenging. Building on the data derived from ex vivo circuit studies, we aimed to develop PK models for antibiotic study drugs that exhibit wide a range of logP and PB in ambulatory healthy sheep (HS) as well as in healthy and critically ill sheep on ECMO. We hypothesised that the drug properties logP and PB can be used to predict PK alterations of antimicrobial drugs during ECMO.

Methods

Ethical approval was obtained from the Queensland University of Technology Animal Ethics Committee (approval number 1100000053) and the University of Queensland Animal Ethics Committee (approval number QUT/194/12). All experimentation was done in accordance with the National Health and Medical Research Council’s Australian Code for the Care and Use of Animals for Scientific Purposes, Eighth Edition (2013) (https://www.nhmrc.gov.au/book/australian-code-care-and-use-animals-scientific-purposes-8th-edition-2013).

Pharmacokinetic sampling

Healthy ambulatory sheep

Seven HS weighing 46–51 kg were housed in a metabolic cart amongst a larger flock, with free access to food and water. Two three-lumen central venous catheters were inserted in the left and right internal jugular veins (IJVs) while the animals were under local anaesthesia for drug administration and PK sampling. The catheters were secured with adhesive glue and a sleeve dressing around the neck. Study drugs were infused for 30 minutes, and serial blood samples were obtained for drug assays using validated chromatographic methods and subsequent PK analysis.

Healthy sheep on ECMO

We performed PK sampling in seven healthy sheep on extracorporeal membrane oxygenation (E24H). A detailed description of our ovine model of venovenous ECMO is provided elsewhere [21, 24]. Briefly, a central venous line was placed in the right IJV while the animals were under local anaesthesia. Alfaxalone, ketamine and midazolam were used for induction and maintenance of anaesthesia. Buprenorphine 0.01 mg/kg was used for supplemental analgesia. Sheep were intubated and ventilated with a Hamilton Galileo ventilator (Hamilton Medical AG, Bonaduz, Switzerland). The facial artery was cannulated for invasive arterial blood pressure monitoring. A pulmonary arterial catheter provided continuous measurements of central venous pressure, mixed venous oxygen saturation and continuous cardiac output (CCO).
Cannulation for ECMO was performed with the animals in supine position. A 21-French (50 cm) CARMEDA BioActive Surface-coated (CBAS; Carmeda, Upplands Väsby, Sweden) venous cannula (Medtronic, Minneapolis, MN, USA) was inserted into the right IJV using a Seldinger technique and positioned using intracardiac echocardiography (ICE) [25] in the proximal inferior vena cava. A 19-French (50 cm) CARMEDA-coated femoral venous cannula was used for return blood and was inserted in the right IJV and positioned at the superior vena cava right atrium using ICE. ECMO pump speeds were titrated to target flows at least two-thirds of pre-ECMO CCO (or 60–80 ml/kg). Immediately upon commencement of ECMO, study drugs were infused for 30 minutes and serial blood samples were obtained for drug assays using validated chromatographic methods and subsequent PK analysis.

Smoke inhalation acute lung injury sheep on ECMO

We performed PK sampling in six sheep with smoke inhalation acute lung injury on ECMO (SE24H). The anaesthesia and ECMO techniques we used are described in the previous section. Smoke inhalation acute lung injury (S-ALI) was induced using a validated, reproducible technique previously published [26]. Briefly, a stainless steel plate was heated to 750 °C and placed on top of 8 g of cotton in a cup. The smoke resulting from combustion collected in the bellows of the purpose-built device was delivered to the sheep by manual compression (tidal volume \[V_T\], 10–12 ml/kg) to achieve a carboxyhaemoglobin content of 45–50 %. The sheep were ventilated using Acute Respiratory Distress Syndrome Network criteria \(V_T\: 4–6\ ml/kg, \text{positive end-expiratory pressure } 10–15\ cm \text{H}_2\text{O}\) for lung-protective ventilation [27]. Once ECMO was established, study drugs were infused for 30 minutes and serial blood samples were obtained for drug assays using validated chromatographic methods and subsequent PK analysis.

Study drugs, drug administration and pharmacokinetic sampling

Following baseline sampling, study drugs in identical doses were administered to the HS, E24H and SE24H groups. The chosen anti-infective study drugs exhibit a wide range of logP and PB (Table 1). The intravenous (IV) study drugs (doses, administration techniques) used were meropenem (500 mg, bolus), ceftriaxone (500 mg, IV bolus), gentamicin (240 mg, slow IV bolus), vancomycin (500 mg in 50 ml 0.9 % saline, IV for 30 minutes), fluconazole (100 mg in 50 ml of 0.9 % saline, IV for 30 minutes), caspofungin (50 mg in 100 ml of 0.9 % saline, IV for 30 minutes), ciprofloxacin (100 mg in 50 ml of 0.9 % saline, IV for 30 minutes) and doripenem (500 mg in 100 ml of 0.9 % saline, IV for 30 minutes). Serial blood samples (2 ml) were obtained at 15, 30, 45, 60, 90, 180, 360, 480 and 720 minutes after commencement of antibiotic drug infusions for drug assays and subsequent PK analysis.

Table 1 Lipophilicity and protein binding characteristics of study drugs

| Study drug         | Lipophilicity (logP) | Protein binding (%) |
|--------------------|----------------------|---------------------|
| Ceftriaxone        | −1.7                 | 95                  |
| Ciprofloxacin      | 2.3                  | 20–40               |
| Caspofungin        | 0.1                  | 97                  |
| Fluconazole        | 0.4                  | 11–12               |
| Gentamicin         | −3.1                 | 0–30                |
| Meropenem          | −0.6                 | 2                   |
| Doripenem          | 0.7                  | 8                   |
| Vancomycin         | −3.1                 | 55                  |

A higher numeric value for octanol-water partition coefficient (logP) indicates greater lipophilicity [29].

Antimicrobial drug assays

Meropenem, doripenem, ceftriaxone and vancomycin analysis was done using high-performance liquid chromatography (HPLC) on a Prominence Ultra Fast system (Shimadzu, Kyoto, Japan) with ultraviolet light detection at 304 nm (meropenem and doripenem) and 230 nm (ceftriaxone and vancomycin). Ciprofloxacin was analysed on a Prominence HPLC system with fluorescence detection at 278 nm (excitation) and 456 nm (emission). Caspofungin, gentamicin and fluconazole analysis was carried out using liquid chromatography–tandem mass spectrometry on a Shimadzu Nexera-8030+ system with detection by positive mode multiple reaction monitoring. Samples were prepared by protein precipitation with trichloroacetic acid (ciprofloxacin and gentamicin), acetonitrile (caspofungin and fluconazole) or acetonitrile with dichloromethane washing (meropenem, ceftriaxone, vancomycin and doripenem). Chromatography was carried out using reversed-phase C18 HPLC columns (meropenem, ceftriaxone, vancomycin, doripenem, ciprofloxacin), reversed-phase C8 HPLC columns (caspofungin, fluconazole) or high-performance liquid chromatography (HPLC) (gentamicin). All methods were validated according to the guidelines of the US Food and Drug Administration [28]. All samples were assayed with internal standards, alongside calibration standards and quality control samples, and met the acceptance criteria.

Statistical analysis and pharmacokinetic modelling

Discrete variables were expressed as count (percentage) and continuous variables as mean ± SD. Demographics and clinical differences between study groups were assessed using a \(\chi^2\) test, Fisher's exact test or Student's t test, as appropriate. \(p < 0.05\) was considered statistically significant.
Table 2: Demographic and physiologic data at baseline after initiation of anaesthesia, mechanical ventilation and haemodynamic monitoring and before smoke inhalation and commencement of ECMO

| Group  | Mean  | SD    | p Value |
|--------|-------|-------|---------|
| Weight, kg | E24H 48.5 4.6 0.84 | SE24H 49.6 4.4 |
| Heart rate, beats/min | E24H 116 13 0.78 | SE24H 118 11 |
| Mean arterial BP, mmHg | E24H 116.1 6.8 0.91 | SE24H 115.7 8.1 |
| Mean PAP, mmHg | E24H 24.6 2.8 0.06 | SE24H 21.2 3.2 |
| CVP, cmH₂O | E24H 15.6 2.8 0.06 | SE24H 12.2 3.2 |
| CCO, L/min | E24H 5.44 0.93 0.33 | SE24H 5.03 0.46 |
| SvO₂, % | E24H 78.8 7.1 0.31 | SE24H 82.0 4.1 |
| PEEP, cmH₂O | E24H 8.1 2.6 0.67 | SE24H 7.5 2.7 |
| Respiratory rate, breaths/min | E24H 10.9 6.0 0.6 | SE24H 12.5 5.2 |
| Fluid balance, ml | E24H 681 376 0.11 | SE24H 926 68 |
| Haemoglobin, g/L | E24H 7.0 1.2 0.47 | SE24H 7.6 1.7 |
| pH | E24H 7.385 0.031 0.62 | SE24H 7.397 0.052 |
| Body temperature, °C | E24H 38.26 0.61 0.67 | SE24H 38.13 0.50 |
| Lactate, mmol/L | E24H 1.34 0.44 0.17 | SE24H 1.07 0.24 |
| Midazolam dose, mg/h | E24H 14.4 1.2 0.17 | SE24H 15.0 0.0 |
| Urine output, ml/h | E24H 69 44 0.87 | SE24H 74 68 |
| Albumin, g/L | E24H 37.16 2.53 0.33 | SE24H 38.15 0.86 |
| Alanine aminotransferase (U/L) | E24H 11.7 2.1 0.51 | SE24H 12.4 1.7 |
| Serum bilirubin, μmol/L | E24H 2.16 0.69 0.75 | SE24H 2.03 0.74 |
| Serum creatinine, μmol/L | E24H 88 15 0.94 | SE24H 87 11 |

Table 2: Demographic and physiologic data at baseline after initiation of anaesthesia, mechanical ventilation and haemodynamic monitoring and before smoke inhalation and commencement of ECMO (Continued)

| Group  | Total protein, g/L | E24H 71.7 6.4 0.78 | SE24H 71.0 1.9 |
|--------|------------------|------------------|----------------|
| Urine creatinine, μmol/L | E24H 10,172 3798 0.17 | SE24H 15,541 8009 |

BP: blood pressure, PAP: pulmonary arterial pressure, CVP: central venous pressure, CCD: continuous cardiac output, SvO₂: mixed venous oxygen saturation, PEEP: positive end-expiratory pressure.

Data presented are derived from comparison of the results between groups: healthy sheep on extracorporeal membrane oxygenation (E24H) (n = 7), sheep with smoke inhalation acute lung injury on extracorporeal membrane oxygenation (SE24H) (n = 6).

A linear mixed effects model was used to examine changes in concentration over time whilst controlling for repeated results from the same sheep. The result adjusts for changes over time and repeated results from the same sheep. The concentration versus time curves (mean ± SEM) were plotted using GraphPad Prism version 5.03 software (GraphPad Software, La Jolla, CA, USA). PK analysis of antibiotic concentrations was undertaken using a non-compartmental approach. All statistical analyses were done using R version 3.1.2 software (R Foundation for Statistical Computing, Vienna, Austria).

We compared the statistical data between the three groups using a box plot. To look for a difference in the mean statistics between groups, we used a linear model with group as the dependent variable. Because the PK data were strongly positively skewed, we log-transformed them before building regression models. Regression models were derived to examine the differences in the following PK parameters between the three study groups: area under the curve (AUC), mean resident time, clearance (CL), steady-state volume of distribution (Vss), maximum plasma concentration and minimum plasma concentration. A linear regression analysis was used to predict PK parameters based on drug properties. logP data for the individual drugs are available from the University of Alberta DrugBank website [29].

Results

We observed no complications during the ECMO run. We found no significant differences between the physiologic variables at the baseline (Table 2). Differences in physiologic variables between the E24H and SE24H groups are presented in Table 3. We found statistically significant differences in pH, haemodynamics, fluid balance and plasma proteins between the E24H and SE24H groups (p < 0.001).

Sixteen hundred samples were analysed for study drug concentrations. Concentration versus time curves for
the study antibiotics are shown in Fig. 1. A summary of
PK parameters estimated using a non-compartmental
analysis is presented in Table 4. Significant differences in
AUC between groups were found for ciprofloxacin, gen-
tamicin and caspofungin. For ciprofloxacin, the most
lipophilic drug studied, there was a significant difference
in Vss between the E24H and SE24H groups (p < 0.004).
For relatively protein-bound drugs, there was a trend
towards increased Vss only in the SE24H group compared
with HS group. However, an increase in CL was seen in
both the E24H and SE24H groups compared with the
HS group for vancomycin (p = 0.02 for both), ceftriaxone
(p = 0.008 and p = 0.05, respectively) and caspofungin
(p < 0.001 for both), which are relatively more
protein-bound.

Scatterplots and linear regression of both CL and Vss
against logP and PB are presented in Figs. 2 and 3.
Table 5 shows regression parameters for predicting study
drug PK using logP and PB. PB exhibited a weaker
negative linear relationship with CL (HS, p < 0.01; E24H,
p < 0.001; SE24H, p < 0.001) and with Vss (HS, p = 0.01;
E24H, p = 0.004; SE24H, p = 0.05). Despite an increased
CL for more protein-bound study drugs, PB in itself was
a predictor of decreased CL in all study groups (Table 5).
logP had a strong positive linear relationship with Vss in
both E24H and SE24H (p < 0.001) but not in HS (p = 0.9).
There was no significant association of logP with CL (HS,
p = 0.55; E24H, p = 0.74; SE24H, p = 0.24).

Discussion
In this study, we systematically investigated the effects of
the ECMO circuit on PK in HS and the combined effects
of ECMO circuit and critical illness on PK in S-ALI sheep
receiving ECMO. In addition, by using antimicrobials with
a range of logP and PB, we were also able to investigate
the relative contributions of drug, circuit and disease fac-
tors influencing PK during ECMO.

There was some expected variability in PK parameters
between the groups. Overall, the main findings of the
study are that (1) a significant increase in Vss for lip-
ophilic drugs that was observed only in the ECMO sheep
and (2) protein-bound drugs exhibited decreased CL
and CL was also more significantly reduced in ECMO
sheep. These findings are significant, as they conform to
PK alterations described in neonates in the clinical
ECMO setting and to emerging PK data in adults, and
they provide further insights into mechanisms behind
these PK alterations.

Although an increase in Vss during ECMO has been
described clinically [12] for many antimicrobial and
sedative drugs, the relative contribution of critical ill-
ness, circuit and drug factors towards this phenomenon
is largely unclear. Systemic inflammation, capillary leak
syndrome and hypoproteinaemia during critical illness
can result in a significantly increased Vss [13]. Similarly,
sequestration of drugs in ECMO circuits may lead to a
further increase in Vss. Equally, a reduction in drug CL
during critical illness may result from renal and hepatic
dysfunction [13]. This study confirms both these find-

ings. An increase in Vss for lipophilic drugs occurred in
both E24H and SE24H but not in HS, clearly highlight-

ing the role of circuit drug sequestration. For all study
drugs except ciprofloxacin, we found no significant dif-
ference in Vss between the E24H and SE24H groups,
Fig. 1 Concentration versus time curves for study drugs. a Meropenem. b Vancomycin. c Ceftriaxone. d Ciprofloxacin. e Fluconazole. f Doripenem. g Caspofungin. h Gentamicin. E24H healthy sheep on extracorporeal membrane oxygenation, HS healthy sheep, SE24H sheep with smoke inhalation acute lung injury on extracorporeal membrane oxygenation.
Table 4 Non-compartmental pharmacokinetic estimates for eight study drugs for all three study groups

| Study drug     | Group | C_{max} (mg/L) | C_{min} (mg/L) | AUC_{0–∞} (mg/h/L) | V_{ss} (L) | Clearance (L/h) | MRT (h) |
|----------------|-------|----------------|----------------|--------------------|-----------|----------------|---------|
| Ceftriaxone    | HS    | 71 (14)        | 0.0 (0.1)      | 202 (46)           | 9.0 (1.8) | 2.6 (0.6)       | 3.5 (0.2) |
|                | E24H  | 86 (15)        | 1.2 (1.4)      | 135 (74)^a         | 63.1 (1.4)^a| 4.3 (1.4)^a     | 1.7 (0.8)^a|
|                | SE24H | 85 (18)        | 1.0 (0.3)^b,c  | 142 (39)           | 7.4 (1.8) | 3.6 (0.8)       | 2.1 (0.6)^b|
| Vancomycin     | HS    | 48 (9)         | 0.0 (0)        | 180 (37)           | 12.4 (2.6) | 2.8 (0.7)       | 4.5 (0.2) |
|                | E24H  | 52 (10)        | 1.59 (0.9)^a   | 131 (60)^a         | 15.7 (3.9) | 4.0 (1.1)^a     | 4.0 (0.6) |
|                | SE24H | 51 (12)        | 2.2 (0.4)^b    | 116 (20)^b         | 19.3 (3.3)^b | 3.9 (0.6)^b     | 4.9 (0.7)^c|
| Gentamicin     | HS    | 20 (2)         | 0.0 (0)        | 78 (7)             | 13.0 (1.3) | 3.1 (0.3)       | 4.3 (0.1) |
|                | E24H  | 12 (6)^a       | 0.3 (0.3)^a    | 25 (12)^a          | 34 (23.5)^a| 12.1 (7.4)^a    | 2.7 (0.5)^a|
|                | SE24H | 16 (2)^b       | 0.6 (0.2)^b,c  | 39 (6.5)^b         | 20.1 (2.9)^b| 5.9 (1.0)^b     | 3.5 (0.7)^b,c|
| Meropenem      | HS    | 26 (16)        | 0.0 (0.1)      | 71 (45)            | 91.0 (138)| 20.9 (28)       | 3.9 (0.8) |
|                | E24H  | 27 (13)        | 0.5 (0.4)      | 36 (26)            | 16.5 (3.0) | 13.8 (4.9)      | 1.4 (0.9)^a|
|                | SE24H | 29 (7)         | 0.3 (0.1)      | 39 (9.0)           | 19.9 (3.7) | 13.2 (2.4)      | 1.6 (0.3)^b|
| Doripenem      | HS    | 26 (17)        | 0.0 (0)        | 73 (47)            | 63.8 (83) | 17.6 (22)       | 3.5 (0.2) |
|                | E24H  | 30 (6)         | 0.0 (0)        | 42 (20)            | 17.1 (2.8) | 15.4 (4.6)      | 1.5 (0.9)^a|
|                | SE24H | 28 (6)         | 0.0 (0)        | 39 (8)             | 20.2 (3.0) | 13.1 (2.4)      | 1.6 (0.2)^b|
| Ciprofloxacin  | HS    | 3.3 (0.5)      | 0.0 (0)        | 13.6 (1.8)         | 31.9 (4.4) | 7.2 (0.9)       | 4.5 (0.3) |
|                | E24H  | 5.1 (1.1)^a    | 0.1 (0.1)^a    | 8.3 (1.5)^a        | 39.0 (7.6)^a| 11.8 (2.5)^a    | 3.5 (1.2)^a|
|                | SE24H | 5.8 (1.2)^b    | 0.1 (0.1)^b,c  | 10.2 (1.5)^b,c     | 52.7 (9.1)^b,c| 8.2 (1.2)^c     | 64.0 (5.0)^b,c|
| Fluconazole    | HS    | 7.7 (0.9)      | 0.0 (0)        | 48.2 (6.2)         | 13.3 (2.2) | 1.2 (0.3)       | 12.0 (5.8) |
|                | E24H  | 9.1 (1.2)^a    | 2.6 (0.8)^d    | 51.0 (5.0)         | 16.7 (2.8)^b| 1.0 (0.3)       | 17.1 (5.5) |
|                | SE24H | 9.2 (1.4)^b    | 2.9 (0.5)^b    | 52.3 (3.5)         | 17.7 (3.4)^b| 0.8 (0.5)^b     | 33.7 (29)^b|
| Caspofungin    | HS    | 5.7 (1.0)      | 0.0 (0)        | 33.8 (7.3)         | 10.0 (2.5) | 0.8 (0.1)       | 12.9 (2.6) |
|                | E24H  | 4.8 (0.8)      | 0.7 (0.2)^a    | 22.3 (6.6)^a       | 14.4 (5.0)^b| 1.9 (0.4)^a     | 7.6 (1.9)^a|
|                | SE24H | 4.3 (1.3)^b    | 0.4 (0.2)^b,c  | 15.5 (3.7)^b,c     | 18.8 (8.4)^b| 2.8 (0.9)^b     | 7.9 (6.4)^b|

HS healthy sheep (n = 7), E24H healthy sheep on extracorporeal membrane oxygenation (n = 6), SE24H sheep with smoke inhalation acute lung injury on extracorporeal membrane oxygenation (n = 6), AUC area under the curve, MRT mean resident time, V_{ss} steady-state volume of distribution, C_{max} maximum plasma concentration, C_{min} minimum plasma concentration

Statistically significant differences between E24H and SE24H groups

Statistically significant differences between E24H and SE24H groups

hence the additional influence of critical illness, if at all, in increasing V_{ss} was less apparent. The reasons behind a greater V_{ss} seen in the case of ciprofloxacin in the SE24H group relative to the E24H group is probably a result of decreased CL in the SE24H group and may indicate altered hepatic metabolism. It should be noted that there was no biochemical evidence of any significant hepatic dysfunction in our model. Clinicians should consider circuit sequestration and alterations in hepatic function when prescribing lipophilic antibiotics. In patients with presumably preserved hepatic function, lipophilic antibiotics may have to be prescribed in higher doses. These findings need further validation in clinical PK studies.

Even though protein-bound drugs have previously been shown to be sequestered in ECMO circuits under physiologic conditions [23] with expected increased V_{ss}, we observed no significant increase in V_{ss} for these drugs in the present study. However, there was a trend towards increased V_{ss} for protein-bound drugs in the SE24H group. This may have resulted from reduced plasma protein concentrations in the SE24H group. The difference in blood pH between the SE24H and E24H groups was significant and may have affected PB [30, 31] and circuit sequestration. Given that unbound drug concentrations were not measured, further interpretation of these data is not possible. From a general PK perspective, protein-bound drugs are expected to have a relatively lower V_{ss}, and during critical illness and ECMO there is a potential for this to increase due to circuit sequestration and other critical illness–induced PK alterations [13]. The net increase in V_{ss} in a critically ill patient on ECMO is therefore challenging to predict on the basis of mechanistic studies alone. Clinical population PK studies are therefore indicated.

Decreases in CL of antimicrobial and other drugs during ECMO have been reported in previous clinical
Antimicrobial CL could not be predicted on the basis of logP in the present study, which suggests that the CL for lipophilic drugs may depend largely on critical illness factors and hepatic drug metabolism. Sequestration of drugs in the ECMO circuit by itself is unlikely to play any significant role in reducing CL for lipophilic drugs. However, it should be noted that alterations in hepatic blood flow [32] and hepatic dysfunction may occur in patients before initiation of ECMO or during ECMO (especially during venoarterial ECMO initiated in patients with severe cardiac failure), which may then adversely affect hepatic metabolism of lipophilic drugs and result in decreased CL. The degree of biochemical hepatic derangement in the SE24H group that received venovenous ECMO for predominant respiratory failure may not have been sufficient to influence metabolism of lipophilic drugs significantly.

Even though protein-bound drugs appeared to have more significantly reduced CL in ECMO sheep in the final model, we observed increased CL in both healthy and critically ill sheep on ECMO for relatively more protein-bound drugs (55% for vancomycin, 95% for ceftriaxone and 97% for caspofungin) compared with HS. Interestingly, these three drugs also demonstrated a trend towards an increased Vss during ECMO, especially in the SE24H group. This is an interesting finding, given that protein-bound drugs have been shown to have a greater propensity for sequestration in ECMO circuits in the ex vivo setting. This relative increase in CL and a trend towards an increased Vss for more protein-bound drugs in ECMO sheep may indicate circuit sequestration. Equally, an increase in plasma unbound fraction of these drugs due to heparin displacement [33] may also have contributed to increased CL and Vss for these drugs. Although this increased CL was apparent in our ovine ECMO models with relatively preserved renal function, this may be of less significance in critically ill patients with significant renal dysfunction or those on continuous renal replacement therapy (CRRT). For example, no significant impact of ECMO on vancomycin CL was observed in a recent clinical population PK study by Donadello et al. [18]. The sheep had normal renal function, at least

![Fig. 2 Scatterplots and regression of clearance against octanol-water partition coefficient and protein binding by groups. Healthy sheep (HS, n = 7), healthy sheep on extracorporeal membrane oxygenation (E24H, n = 7), sheep with smoke inhalation acute lung injury on extracorporeal membrane oxygenation (SE24H, n = 6)
biochemically, as opposed to 7 of 11 patients who received CRRT in the above-mentioned study. This is an important point to note because kidney injury and relatively lower CL for vancomycin achieved on CRRT may have negated an increase in CL during ECMO.

Although ex vivo studies confirm relative stability of vancomycin in ECMO circuits, they do not replicate the in vivo situation. A recent ex vivo study showed that, with drugs with similar PB, lipophilicity becomes the determinant of eventual circuit loss. Vancomycin, although relatively protein-bound (55 %), is hydrophilic. Hence, it is possible that, in the in vivo setting, there is a greater propensity for hydrophilic protein-bound drugs to undergo circuit sequestration. Appropriately powered clinical population PK studies in which investigators compare vancomycin PK in ECMO patients with and without preserved renal function are needed to address this further, and such studies are currently underway [34].

In summary, sequestration of lipophilic antibiotics plays an important role in increasing their $V_{ss}$ during ECMO. CL of lipophilic drugs is largely dependent on hepatic drug metabolism, which can be significantly

### Table 5 Linear regression parameters for predicting PK parameters using drug properties

| Group | Dependent | Independent | Mean  | Lower | Upper | $p$ Value |
|-------|-----------|-------------|-------|-------|-------|-----------|
| HS    | CL        | logP        | −0.54 | −2.37 | 1.29  | 0.556     |
| E24H  | CL        | logP        | −0.12 | −0.86 | 0.62  | 0.744     |
| SE24H | CL        | logP        | −0.41 | −1.09 | 0.28  | 0.235     |
| HS    | PB        |            | −0.13 | −0.22 | −0.03 | 0.01      |
| E24H  | CL        | PB          | −0.08 | −0.11 | −0.04 | <0.001    |
| SE24H | CL        | PB          | −0.07 | −0.10 | −0.04 | <0.001    |
| HS    | $V_{ss}$  | logP        | −0.48 | −8.43 | 7.46  | 0.003     |
| E24H  | $V_{ss}$  | logP        | 2.85  | 1.73  | 3.97  | <0.001    |
| SE24H | $V_{ss}$  | logP        | 3.84  | 2.18  | 5.50  | <0.001    |
| HS    | $V_{ss}$  | PB          | −0.50 | −0.92 | −0.09 | 0.017     |
| E24H  | $V_{ss}$  | PB          | −0.10 | −0.17 | −0.04 | 0.004     |
| SE24H | $V_{ss}$  | PB          | −0.10 | −0.21 | 0.00  | 0.056     |

*PB* protein binding, *logP* octanol-water partition coefficient (measure of drug lipophilicity)
affected in a subgroup of ECMO patients receiving venoarterial ECMO for cardiac failure. Although more protein-bound drugs were found to have relatively higher CL in this study, PB in isolation may not be a reliable predictor of CL. Patients on ECMO may have significant renal dysfunction, which is more likely to influence the net CL than sequestration alone. Overall, ECMO appears to decrease antimicrobial CL. These findings need further validation in clinical studies, and such studies are currently underway [34]. This animal study has limitations. Apart from inherent PK variability that is expected in a small sample, the distribution, metabolism and excretion processes in sheep may differ from those of humans. Despite the SE24H group’s development of severe cardiorespiratory failure following S-ALI, the degree of hepatic and renal dysfunction may not have been sufficient to more fully elucidate the full impact of critical illness of PK. However, the changes in PK due to critical illness are very well described, and the use of a model with no advanced end-organ failures that is designed to more fully examine the circuit–drug interactions is justified. Also, this study was directed more at observing relative PK changes between groups and the effects of drug factors logP and PB on antibiotic PK.

Conclusions
Lipophilic antimicrobial agents are likely to have an increased Vss and decreased CL during ECMO. Protein-bound antibiotics are likely to have reductions in both CL and Vss during ECMO. The strong relationship between logP and Vss during ECMO indicates circuit sequestration of lipophilic drugs. These findings highlight the importance of drug factors in predicting antibiotic drug PK during ECMO and should be a consideration when performing and interpreting population PK studies.

Key messages
- Sequestration of lipophilic antibiotics results in increased Vss on ECMO.
- Lipophilic drugs exhibit a larger Vss during ECMO, and lipophilicity by itself has little impact on drug CL.
- Protein-bound drugs may have decreased Vss and CL during ECMO.
- Higher doses of lipophilic antibiotics may be indicated in patients with intact hepatic function.
- Lipophilicity and PB are useful drug factors to use in predicting antibiotic PK during ECMO.

Abbreviations
ALT: alanine aminotransferase; AST: aspartate aminotransferase; AUC: area under the curve; BP: blood pressure; CL: clearance; Cmax: maximum plasma concentration; Cmin: minimum plasma concentration; CCO: continuous cardiac output; CRRT: continuous renal replacement therapy; CsHb: concentration of total blood haemoglobin; CVP: central venous pressure; E24H: healthy sheep on extracorporeal membrane oxygenation; ECLS: extracorporeal life support; ECMO: extracorporeal membrane oxygenation; FiO2: fraction inspired oxygen; HPLC: high-performance liquid chromatography; HS: healthy sheep; ICE: intra-cardiac echocardiography; KLU: intensive care unit; LVEF: left ventricular ejection fraction; MRT: mean resident time; paCO2: partial pressure of carbon dioxide; paO2: partial pressure of oxygen; PAP: pulmonary arterial pressure; PB: protein binding; PEEP: positive end-expiratory pressure; PK: pharmacokinetic; S-ALI: smoke inhalation acute lung injury; SE24H: sheep with smoke inhalation acute lung injury on extracorporeal membrane oxygenation; SVo2: mixed venous oxygen saturation; Vss: steady-state volume of distribution; Vt: tidal volume.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
KS designed the study and wrote the draft study protocol, wrote grant applications to support drug assays, analysed data and wrote the draft manuscript. JAR assisted with protocol development and edited and critically evaluated the manuscript. JFF and YLF led the team that wrote the grant to secure funding for the animal ECMO experiment. JFF, YLF, SD and KS developed the animal model with assistance from many other research team members listed in the Acknowledgements section. AGB assisted with statistical and PK analysis. SCW carried out antibiotic drug assays; AGB, SD, JFF, SCW and YLF edited and critically evaluated the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors acknowledge Lynnette Munck, Kimble R Dunster, Margaret Passmore, Gabriella Simonova, Charles McDonald, Sam Foley and Suzanne Parker for assistance with the study. This work was supported in part by funding provided by the National Health and Medical Research Council, the Australian and New Zealand College of Anaesthetists, the Intensive Care Foundation and the Prince Charles Hospital Foundation. JAR is funded by a National Health and Medical Research Council of Australia Training Research Foundation and the Prince Charles Hospital Foundation. JFF, KS and YLF are supported by the Australian and New Zealand College of Anaesthetists, the Intensive Care Foundation and the Prince Charles Hospital Foundation. The authors acknowledge Lynnette Munck, Kimble R Dunster, Margaret Passmore, Gabriella Simonova, Charles McDonald, Sam Foley and Suzanne Parker for assistance with the study. This work was supported in part by funding provided by the National Health and Medical Research Council, the Australian and New Zealand College of Anaesthetists, the Intensive Care Foundation and the Prince Charles Hospital Foundation. JAR is funded by a National Health and Medical Research Council of Australia Training Research Foundation (409931). JFF currently holds a Health Research Fellowship awarded by the Office of Health and Medical Research, Queensland, Australia.

Author details
1.Critical Care Research Group, The Prince Charles Hospital, Rode Road, Chermside, QLD 4032, Australia.
2.Discipline of Anaesthetics and Critical Care, The University of Queensland, Brisbane QLD, Australia.
3.Burns Trauma and Critical Care Research Centre, The University of Queensland, Brisbane, QLD, Australia.
4.Institute of Health and Biomedical Innovation, School of Public Health & Social Work, Queensland University of Technology, Brisbane, QLD, Australia.
5.School of Health and Sports Science, University of the Sunshine Coast, Sippy Downs, QLD, Australia.

Received: 12 June 2015 Accepted: 30 November 2015
Published online: 15 December 2015

References
1. Shekar K. Extracorporeal respiratory support: breaking conventions? Anaesth Intensive Care. 2014;42(2):175–7.
2. Brodie D, Bacchetta M. Extracorporeal membrane oxygenation for ARDS in adults. N Engl J Med. 2011;365(20):1905–14.
3. Abrams D, Combes A, Brodie D. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am Coll Cardiol. 2014;63(25 Pt A):2769–78.
4. Shekar K, Mullany DV, Thomson B, Ziegenfuss M, Platts DG, Fraser JF. Extracorporeal life support devices and strategies for management of acute cardiorespiratory failure in adult patients: a comprehensive review. Crit Care. 2014;18(3):219.
5. Barbaro RP, Odetola FO, Kidwell KM, Paden ML, Bartlett RH, Davis MM, et al. Association of hospital-level volume of extracorporeal membrane oxygenation cases and mortality. Analysis of the extracorporeal life support organization registry. Am J Respir Crit Care Med. 2015;191(8):894–901.
6. Shekar K, Fraser JF, Roberts JA. Can optimal drug dosing during ECMO improve outcomes? Intensive Care Med. 2013;39(12):2237.
7. Mackelren G, Burt W. Extracorporeal membrane oxygenation and sepsis. Crit Care Resusc. 2007;9(1):76–80.
8. Roberts JA, Krueger P, Paterson DL, Lipman J. Antibiotic resistance—what’s dosing got to do with it? Crit Care Med. 2008;36(8):2433–40.
9. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet. 2006;45(8):755–73.
10. Aubron C, Cheng AC, Pitcher D, Leong T, Magrin G, Cooper DJ, et al. Infections acquired by adults who receive extracorporeal membrane oxygenation: risk factors and outcome. Infect Control Hosp Epidemiol. 2013;34(1):24–30.
11. Bizzarro MJ, Conrad SA, Kaufman DA, Rycus P. Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults. Pediatr Crit Care Med. 2011;12(3):277–81.
12. Shekar K, Fraser JF, Smith MT, Roberts JA. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care. 2012;27(6):741, e9–18.
13. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840–51.
14. Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin Pharmacokinet. 2003;42(5):403–17.
15. Cohen P, Collart L, Prober CG, Fischer AF, Blaschke TF. Gentamicin pharmacokinetics in neonates undergoing extracorporeal membrane oxygenation. Pediatr Infect Dis J. 1990;9(8):562–6.
16. Dagan O, Klein I, Gruenwald C, Bohn D, Barker G, Koren G. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit. 1993;15(4):263–6.
17. Shekar K, Fraser JF, Taccone FS, Welch S, Wallis SC, Mullany DV, et al. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. Crit Care. 2014;18(5):565.
18. Donadello K, Roberts JA, Cristallini S, Beumer M, Shekar K, Jacobs F, et al. Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study. Crit Care. 2014;18(6):632.
19. Donadello K, Antonucci E, Cristallini S, Roberts JA, Beumer M, Scollozza S, et al. β-Lactam pharmacokinetics during extracorporeal membrane oxygenation: a case–control study. Int J Antimicrob Agents. 2015;45(2):278–82.
20. Lemaître F, Luyt CE, Rouillet-Renoleau F, Nieszowska A, Zahr N, Convol E, et al. Impact of extracorporeal membrane oxygenation and continuous venovenous hemofiltration on the pharmacokinetics of ceftazidime in critically ill patients with pandemic (H1N1) influenza. Ther Drug Monit. 2012;34(2):171–5.
21. Shekar K, Roberts JA, Smith MT, Fung YL, Fraser JF. The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation. BMC Anesthesiol. 2013;13:7.
22. Shekar K, Roberts JA, McDonald CI, Fisquet S, Barnett AG, Mullany DV, et al. Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care. 2012;16(5):R194.
23. Shekar K, Roberts JA, McDonald CI, Ghassabian S, Anstey C, Wallis SC, et al. Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. Crit Care. 2015;19(1):164.
24. Shekar K, Fung YL, Diab S, Mullany DV, McDonald CI, Dunster KR, et al. Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions. Crit Care Resusc. 2012;14(2):105–11.
25. Platts DG, Sedgwick JF, Burstow DJ, Mullany DV, Fraser JF. The role of echocardiography in the management of patients supported by extracorporeal membrane oxygenation. J Am Soc Echocardiogr. 2012;25(2):131–41.
26. Riedel T, Fraser JF, Dunster K, Fitzgibbon J, Schibler A. Effect of smoke inhalation on viscoelastic properties and ventilation distribution in sheep. J Appl Physiol. 2006;101(3):763–70.
27. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301–8.
28. US Food and Drug Administration. Guidance for industry: bioanalytical method validation. Rockville, MD: US Department of Health and Human Services, Center for Drug Evaluation and Research; 2001. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/GuidancesUCM070107.pdf. Accessed 6 Dec. 2015.
29. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tsur D, et al. DrugBank: a knowledge base for drugs, drug actions and drug targets. Nuclie Acids Res. 2008;36(Database issue):D901–6.
30. Hinderling PH, Hartmann D. The pH dependency of the binding of drugs to plasma proteins in man. Ther Drug Monit. 2005;27(1):71–85.
31. Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, et al. Protein binding: do we ever learn? Antimicrobial Agents Chemotherapy. 2011;55(7):3067–74.
32. Chauhan S, Subin S. Extracorporeal membrane oxygenation, an anesthesiologist’s perspective: physiology and principles. Part 1. An Card Anaesth. 2011;14(3):218–29.
33. Keller F, Maiga M, Neumayer HH, Lode H, Distler A. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. Eur J Drug Metab Pharmacokinet. 1984(9):275–82.
34. Shekar K, Roberts JA, Welch S, Buscher H, Rudham S, Burrows F, et al. ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO. BMC Anesthesiol. 2012;12:29.